BR112014016939A2 - ácidos nucleicos que se ligam especificamente a cgrp - Google Patents
ácidos nucleicos que se ligam especificamente a cgrpInfo
- Publication number
- BR112014016939A2 BR112014016939A2 BR112014016939A BR112014016939A BR112014016939A2 BR 112014016939 A2 BR112014016939 A2 BR 112014016939A2 BR 112014016939 A BR112014016939 A BR 112014016939A BR 112014016939 A BR112014016939 A BR 112014016939A BR 112014016939 A2 BR112014016939 A2 BR 112014016939A2
- Authority
- BR
- Brazil
- Prior art keywords
- cgrp
- nucleic acids
- specifically bind
- acid molecule
- nucleic acid
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 239000005547 deoxyribonucleotide Substances 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000105 | 2012-01-10 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| PCT/EP2013/000055 WO2013104539A1 (en) | 2012-01-10 | 2013-01-10 | Nucleic acids specifically binding cgrp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014016939A2 true BR112014016939A2 (pt) | 2019-09-24 |
Family
ID=48781062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014016939A BR112014016939A2 (pt) | 2012-01-10 | 2013-01-10 | ácidos nucleicos que se ligam especificamente a cgrp |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9163243B2 (https=) |
| EP (1) | EP2802659A1 (https=) |
| JP (1) | JP2015506174A (https=) |
| KR (1) | KR20140111704A (https=) |
| CN (1) | CN104136612A (https=) |
| AU (1) | AU2013209130A1 (https=) |
| BR (1) | BR112014016939A2 (https=) |
| CA (1) | CA2860809A1 (https=) |
| HK (1) | HK1198370A1 (https=) |
| IL (1) | IL233515A0 (https=) |
| MX (1) | MX2014008456A (https=) |
| RU (1) | RU2014132706A (https=) |
| SG (1) | SG11201403769YA (https=) |
| WO (1) | WO2013104539A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013104540A1 (en) | 2012-01-10 | 2013-07-18 | Noxxon Pharma Ag | New c5a binding nucleic acids |
| PE20161439A1 (es) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
| JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
| EA201890578A1 (ru) * | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
| ES2607639B1 (es) | 2015-09-30 | 2018-02-28 | Urquima, S.A | Sal de ácido maleico de un intermedio de silodosina |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| KR102929968B1 (ko) * | 2018-11-12 | 2026-02-25 | 아프타리온 바이오테크 아게 | Cxcl8 결합 핵산 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| AU732820B2 (en) | 1995-06-02 | 2001-05-03 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| DE69433747D1 (de) | 1994-08-16 | 2004-06-03 | Human Genome Sciences Inc | Calcitoninrezeptor |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| RU2180311C1 (ru) | 2001-07-05 | 2002-03-10 | Мешалкин Георгий Алексеевич | Защитная пробка |
| US7629456B2 (en) | 2001-10-26 | 2009-12-08 | Noxxon Pharma Ag | Modified L-nucleic acid |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| US7879991B2 (en) * | 2002-05-06 | 2011-02-01 | Noxxon Pharma Ag | CGRP binding nucleic acids |
| MXPA05011022A (es) | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US20090281296A1 (en) | 2004-02-09 | 2009-11-12 | Supramol Parenteral Colloid Gmbh | Process for the production of conjugates from polysaccharides and polynucelotides |
| MXPA06010782A (es) | 2004-03-23 | 2007-03-28 | Complex Biosystems Gmbh | Ligador de profarmaco. |
| CN101098703B (zh) | 2004-11-05 | 2011-08-03 | 费城儿童医院 | 用于分子治疗的生物降解连接剂 |
| EP1877069A2 (de) * | 2005-05-04 | 2008-01-16 | Noxxon Pharma AG | Neue verwendung von spiegelmeren |
| JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| WO2008052774A2 (en) | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
| US8871920B2 (en) | 2010-04-21 | 2014-10-28 | Noxxon Pharma Ag | Lipid binding nucleic acids |
| AU2012206750A1 (en) * | 2011-01-10 | 2013-07-18 | Noxxon Pharma Ag | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
-
2013
- 2013-01-10 EP EP13700455.2A patent/EP2802659A1/en not_active Withdrawn
- 2013-01-10 KR KR1020147022328A patent/KR20140111704A/ko not_active Withdrawn
- 2013-01-10 RU RU2014132706A patent/RU2014132706A/ru not_active Application Discontinuation
- 2013-01-10 MX MX2014008456A patent/MX2014008456A/es unknown
- 2013-01-10 US US14/371,210 patent/US9163243B2/en not_active Expired - Fee Related
- 2013-01-10 CN CN201380009019.6A patent/CN104136612A/zh active Pending
- 2013-01-10 AU AU2013209130A patent/AU2013209130A1/en not_active Abandoned
- 2013-01-10 SG SG11201403769YA patent/SG11201403769YA/en unknown
- 2013-01-10 BR BR112014016939A patent/BR112014016939A2/pt not_active IP Right Cessation
- 2013-01-10 HK HK14111873.3A patent/HK1198370A1/xx unknown
- 2013-01-10 CA CA2860809A patent/CA2860809A1/en not_active Abandoned
- 2013-01-10 WO PCT/EP2013/000055 patent/WO2013104539A1/en not_active Ceased
- 2013-01-10 JP JP2014551569A patent/JP2015506174A/ja active Pending
-
2014
- 2014-07-03 IL IL233515A patent/IL233515A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140111704A (ko) | 2014-09-19 |
| US9163243B2 (en) | 2015-10-20 |
| MX2014008456A (es) | 2014-11-25 |
| HK1198370A1 (en) | 2015-04-10 |
| IL233515A0 (en) | 2014-08-31 |
| RU2014132706A (ru) | 2016-02-27 |
| AU2013209130A1 (en) | 2014-07-10 |
| CA2860809A1 (en) | 2013-07-18 |
| EP2802659A1 (en) | 2014-11-19 |
| JP2015506174A (ja) | 2015-03-02 |
| SG11201403769YA (en) | 2014-07-30 |
| US20150031755A1 (en) | 2015-01-29 |
| CN104136612A (zh) | 2014-11-05 |
| WO2013104539A1 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014016939A2 (pt) | ácidos nucleicos que se ligam especificamente a cgrp | |
| BR112014016877A2 (pt) | ácidos nucleicos de ligação a c5a | |
| CY1123973T1 (el) | Συνθεσεις και μεθοδοι για ακριβη ταυτοποιηση μεταλλαξεων | |
| SG11201809961TA (en) | Variants of a dna polymerase of the polx family | |
| MX2020007022A (es) | Moleculas de enlace a il-18. | |
| PH12020500103A1 (en) | Use of cas protein, method for detecting target nucleic acid molecule, and kit | |
| EP2652153A4 (en) | DNA SEQUENCING BY SYNTHESIS USING MODIFIED NUCLEOTIDES AND NANOPORENT DETECTION | |
| CL2011002664A1 (es) | Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. | |
| EP2756101A4 (en) | SAMPLE: ANTIPROBE COMPOSITIONS FOR DETECTION OF HIGH-SPECIFIC DNA OR RNA | |
| EP2912175A4 (en) | COMPOSITION FOR CUTTING A TARGET DNA WITH A LEAD DNA SPECIFIC TO THE TARGET DNA AND FOR CAS PROTEIN-CODING NUCLEIC ACID OR CAS PROTEIN AND USE THEREOF | |
| EP4520841A3 (en) | Enzyme- and amplification-free sequencing | |
| BRPI0918670B8 (pt) | anticorpo | |
| BRPI0713503A2 (pt) | Promotor sintético induzível por patógeno | |
| BR112014019047A2 (pt) | análise de dados de sequências de dna | |
| EP4481045A3 (en) | Dna-binding protein using ppr motif, and use thereof | |
| WO2008087641A3 (en) | H19 silencing nucleic acid agents for treating rheumatoid arthritis | |
| WO2012103442A3 (en) | Paired end bead amplification and high throughput sequencing | |
| TR201904440T4 (tr) | Dna kütüphanelerinin hazırlanması için dna-adaptör molekülleri ve bunların üretilmesi için yöntem ve kullanımları. | |
| IL277813A (en) | Tm-enhanced double-helix nucleic acid tracer molecules with nucleotides | |
| BR112014012773A2 (pt) | ensaio de polimorfismo de nucleotídeo único de alto rendimento | |
| CY1116033T1 (el) | Συντηγμενοι κοκκοι αργιλιου-ζιρκονιου | |
| WO2015150482A8 (en) | A combination product comprising a nucleic acid structure and a single-stranded nucleic acid molecule | |
| EP2627332A4 (en) | PROTON-COUPLED SELECTIVE FOLATTRANSPORTER AND FOLAT RECEPTOR, HEMMER COMPOUNDS WITH GARFTASE AND / OR OTHER FOLATMETABOLIZATION ENZYMS AND METHOD OF USE THEREOF | |
| WO2009130296A3 (en) | Anti-alk1 antibodies and uses thereof | |
| MX377713B (es) | Moleculas de ácido ribonucleico pequeño de interferencia especifico de notch 1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |